SCHEMBL16645246

SCHEMBL16645246

COC(=O)C(N)Cc1c[nH]c2cc(OC)ccc12

nearest known ligand 0.70

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 1/20 0.58
MTNR1B P49286 1/20 0.58
HTR2A P28223 2/20 0.57
HTR1A P08908 1/20 0.57
HTR2C P28335 1/20 0.57
HTR2B P41595 1/20 0.57
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
SOS1 Q07889 1/20 0.53
SCN9A Q15858 1/20 0.52
MAPT P10636 2/20 0.51
HTR6 P50406 1/20 0.51
TACR1 P25103 2/20 0.50
HPGD P15428 1/20 0.49
MAPK1 P28482 1/20 0.49
ADRB3 P13945 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17938401 1.00 MTNR1A (0.58) MTNR1AMTNR1BHTR2AHTR1AHTR2C
SCHEMBL21384322 0.90 SCN9A (0.60) MTNR1AMTNR1BHTR2AHTR1AHTR2C
SCHEMBL6301729 0.90 SCN9A (0.60) MTNR1AMTNR1BHTR2AHTR1AHTR2C
SCHEMBL30663629 0.90 SCN9A (0.60) MTNR1AMTNR1BHTR2AHTR1AHTR2C
SCHEMBL1196470 0.90 HTR2B (0.68) MTNR1AMTNR1BHTR2AHTR1AHTR2C
SCHEMBL6302625 0.90 HTR2B (0.68) MTNR1AMTNR1BHTR2AHTR1AHTR2C
Hydrochloric Acid SCHEMBL28152945 0.89 HTR2B (0.67) MTNR1AMTNR1BHTR2AHTR1AHTR2C
Hydrochloric Acid SCHEMBL28152940 0.89 HTR2B (0.67) MTNR1AMTNR1BHTR2AHTR1AHTR2C
SCHEMBL18029114 0.89 KMT2A (0.61) MTNR1AMTNR1BHTR2AHTR1AHTR2C
SCHEMBL1460676 0.89 KMT2A (0.61) MTNR1AMTNR1BHTR2AHTR1AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117801004-A Method for alkynyl at four-position of indole carbon based on C-H bond activation 上海交通大学 2024-04-02 CN disclosed
US-9695174-B2 Inhibitor of breast cancer resistance protein (BCRP) MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-07-04 US disclosed
US-9695174-B2 Inhibitor of breast cancer resistance protein (BCRP) MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-07-04 US disclosed
US-9695174-B2 Inhibitor of breast cancer resistance protein (BCRP) MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-07-04 US disclosed
US-20160214984-A1 INHIBITOR OF BREAST CANCER RESISTANCE PROTEIN (BCRP) TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-07-28 US disclosed
US-20160214984-A1 INHIBITOR OF BREAST CANCER RESISTANCE PROTEIN (BCRP) TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-07-28 US disclosed
US-20160214984-A1 INHIBITOR OF BREAST CANCER RESISTANCE PROTEIN (BCRP) TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-07-28 US disclosed
WO-2015054132-A1 INHIBITOR OF BREAST CANCER RESISTANCE PROTEIN (BCRP) MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160214984-A1 INHIBITOR OF BREAST CANCER RESISTANCE PROTEIN (BCRP) BRCA1, ABCC1, IMPA1 MTNR1A 364/4885MTNR1B 270/4885HTR2A 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.